[go: up one dir, main page]

WO2001085209A3 - Traitement de maladies induites par les lymphocytes t par modulation de l'activite de dr6 - Google Patents

Traitement de maladies induites par les lymphocytes t par modulation de l'activite de dr6 Download PDF

Info

Publication number
WO2001085209A3
WO2001085209A3 PCT/US2001/011735 US0111735W WO0185209A3 WO 2001085209 A3 WO2001085209 A3 WO 2001085209A3 US 0111735 W US0111735 W US 0111735W WO 0185209 A3 WO0185209 A3 WO 0185209A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell mediated
modulating
treating
activity
mediated diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/011735
Other languages
English (en)
Other versions
WO2001085209A2 (fr
Inventor
Josef Georg Heuer
Jinqi Liu
Songqing Na
Ho Yeong Song
Derek Di Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to US10/257,907 priority Critical patent/US20040043022A1/en
Priority to EP01930475A priority patent/EP1282441A2/fr
Priority to AU2001257008A priority patent/AU2001257008A1/en
Publication of WO2001085209A2 publication Critical patent/WO2001085209A2/fr
Publication of WO2001085209A3 publication Critical patent/WO2001085209A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur de nouveaux procédés utiles dans le traitement ou la prévention d'états pathologiques induits par les lymphocytes T chez un mammifère, ce procédé consistant à administrer au mammifère une quantité efficace d'un point de vue thérapeutique d'une composition pharmaceutique comprenant au moins un agoniste ou un antagoniste de DR6.
PCT/US2001/011735 2000-05-10 2001-04-30 Traitement de maladies induites par les lymphocytes t par modulation de l'activite de dr6 Ceased WO2001085209A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/257,907 US20040043022A1 (en) 2001-04-30 2001-04-30 Treating t-cell mediated diseases by modulating dr6 activity
EP01930475A EP1282441A2 (fr) 2000-05-10 2001-04-30 Traitement de maladies induites par les lymphocytes t par modulation de l'activite de dr6
AU2001257008A AU2001257008A1 (en) 2000-05-10 2001-04-30 Treating t-cell mediated diseases by modulating dr6 activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20301500P 2000-05-10 2000-05-10
US60/203,015 2000-05-10

Publications (2)

Publication Number Publication Date
WO2001085209A2 WO2001085209A2 (fr) 2001-11-15
WO2001085209A3 true WO2001085209A3 (fr) 2002-04-04

Family

ID=22752104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011735 Ceased WO2001085209A2 (fr) 2000-05-10 2001-04-30 Traitement de maladies induites par les lymphocytes t par modulation de l'activite de dr6

Country Status (3)

Country Link
EP (1) EP1282441A2 (fr)
AU (1) AU2001257008A1 (fr)
WO (1) WO2001085209A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455825A4 (fr) * 2001-12-17 2006-05-31 Lilly Co Eli Traitement de maladies mediees par les lymphocytes b par modulation de l'activite du dr6
KR20110089185A (ko) 2008-11-25 2011-08-04 바이오겐 아이덱 엠에이 인코포레이티드 신경계 세포의 생존을 촉진하기 위한 ｄｒ６ 및 ｐ７５ 길항제의 용도
CN102735841B (zh) * 2011-04-13 2014-11-05 苏州卫生职业技术学院 一种测定Graves病患者血液中可溶性CD28含量的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056892A1 (fr) * 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Recepteur humain tr9 du facteur de necrose tumorale
WO1999015663A1 (fr) * 1997-09-26 1999-04-01 Millennium Pharmaceuticals, Inc. Nouvelles molecules de la super-famille des recepteurs de tnf et utilisations de ces molecules
WO1999043839A1 (fr) * 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccins, agents d'immunotherapie et procedes pour leur utilisation
WO2000056862A1 (fr) * 1999-03-24 2000-09-28 Human Genome Sciences, Inc. Recepteur tr9 humain de facteurs de necrose des tumeurs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056892A1 (fr) * 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Recepteur humain tr9 du facteur de necrose tumorale
WO1999015663A1 (fr) * 1997-09-26 1999-04-01 Millennium Pharmaceuticals, Inc. Nouvelles molecules de la super-famille des recepteurs de tnf et utilisations de ces molecules
WO1999043839A1 (fr) * 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccins, agents d'immunotherapie et procedes pour leur utilisation
WO2000056862A1 (fr) * 1999-03-24 2000-09-28 Human Genome Sciences, Inc. Recepteur tr9 humain de facteurs de necrose des tumeurs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. PAN ET AL.: "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor.", FEBS LETTERS, vol. 431, no. 3, 24 July 1998 (1998-07-24), Amsterdam, The Netherlands, pages 351 - 356, XP002113408 *

Also Published As

Publication number Publication date
WO2001085209A2 (fr) 2001-11-15
AU2001257008A1 (en) 2001-11-20
EP1282441A2 (fr) 2003-02-12

Similar Documents

Publication Publication Date Title
TNSN07312A1 (en) Combination of organic compounds
CA2370030A1 (fr) Composition de blocage du canal sodique et leur utilisation
WO2004034988A3 (fr) Anticorps humains neutralisants anti-ifn-$g(g) utilises comme inhibiteurs selectifs des voies de ifn-$g(g)
WO2008050329A3 (fr) NOUVEAUX ARNsi ET PROCÉDÉS D'UTILISATION DE CEUX-CI
WO2002043652A3 (fr) Medicaments anti-proliferation
MXPA02012763A (es) Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus.
WO2006133955A8 (fr) Compositions contenant adamts13, presentant une activite thrombolytique
GB0001449D0 (en) Compositions
WO2005016326A3 (fr) Analogues de la thalidomide utilises comme inhibiteurs potentiels de l'angiogenese
WO2008157537A3 (fr) Compositions et procédés d'utilisation pour traiter ou prévenir des troubles liés aux lipides
AR019671A1 (es) Uso de una cantidad terapeuticamente efectiva de (+) norcisaprida o una sal farmacologicamente aceptable de la misma sustancialmente libre de su (-)estereoisomero, para la preparacion de un medicamento
WO2003051290A3 (fr) Traitement de maladies mediees par les lymphocytes b par modulation de l'activite du dr6
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
WO2008063768A3 (fr) Compositions et procédés pour traiter des maladies métaboliques
WO2004012762A3 (fr) Methode et composition pour la protection du tissu neuronal contre une lesion induite par des taux de glutamate eleves
WO2003092606A3 (fr) Inhibiteurs de cholinesterase pour prevenir les blessures causees par des produits chimiques
WO2006012641A3 (fr) Procedes de detection et de traitement de troubles auto-immuns
WO2007056324A3 (fr) Combinaison de composes organiques pour le traitement des maladies cardiovasculaires
WO2005115432A3 (fr) Traitement de maladies et de troubles oculaires utilisant des compositions lantibiotiques
WO2006020680A3 (fr) Composes heterocycliques comme agents pharmaceutiques
WO2005009363A3 (fr) Traitements d'etats precancereux et prevention du cancer au moyen de therapies a base de pcdgf
WO2005123192A3 (fr) Procede ameliorant le traitement medical de la douleur
WO2006061715A3 (fr) Derives de methylene
WO2001085209A3 (fr) Traitement de maladies induites par les lymphocytes t par modulation de l'activite de dr6

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10257907

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001930475

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001930475

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001930475

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP